NO20004433L - Ligandscreening og design ved røntgenkrystallografi - Google Patents

Ligandscreening og design ved røntgenkrystallografi

Info

Publication number
NO20004433L
NO20004433L NO20004433A NO20004433A NO20004433L NO 20004433 L NO20004433 L NO 20004433L NO 20004433 A NO20004433 A NO 20004433A NO 20004433 A NO20004433 A NO 20004433A NO 20004433 L NO20004433 L NO 20004433L
Authority
NO
Norway
Prior art keywords
biomolecule
crystal
ligand
test samples
target
Prior art date
Application number
NO20004433A
Other languages
English (en)
Other versions
NO20004433D0 (no
Inventor
Vicki L Nienaber
Jonathan Greer
Calerino Abad-Zapatero
Daniel W Norbeck
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO20004433D0 publication Critical patent/NO20004433D0/no
Publication of NO20004433L publication Critical patent/NO20004433L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9723—Urokinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Organic Chemistry (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20004433A 1998-03-06 2000-09-05 Ligandscreening og design ved røntgenkrystallografi NO20004433L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3618498A 1998-03-06 1998-03-06
PCT/US1999/004967 WO1999045379A2 (en) 1998-03-06 1999-03-05 Ligand screening and design by x-ray crystallography

Publications (2)

Publication Number Publication Date
NO20004433D0 NO20004433D0 (no) 2000-09-05
NO20004433L true NO20004433L (no) 2000-11-06

Family

ID=21887121

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004433A NO20004433L (no) 1998-03-06 2000-09-05 Ligandscreening og design ved røntgenkrystallografi

Country Status (18)

Country Link
US (1) US6297021B1 (no)
EP (1) EP1068531B1 (no)
JP (1) JP2002506206A (no)
KR (1) KR20010041653A (no)
CN (2) CN100354627C (no)
AT (1) ATE375510T1 (no)
AU (3) AU2887099A (no)
BG (1) BG104802A (no)
BR (1) BR9908563A (no)
CA (1) CA2321968A1 (no)
DE (1) DE69937292T2 (no)
HU (1) HUP0101959A3 (no)
IL (1) IL137758A0 (no)
NO (1) NO20004433L (no)
PL (1) PL343264A1 (no)
SK (1) SK13242000A3 (no)
TR (4) TR200101200T2 (no)
WO (2) WO1999045389A2 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030049678A1 (en) * 1999-03-05 2003-03-13 Nienaber Vicki L. Ligand screening and design by X-ray crystallography
US7250305B2 (en) 2001-07-30 2007-07-31 Uab Research Foundation Use of dye to distinguish salt and protein crystals under microcrystallization conditions
US20020164812A1 (en) * 1999-04-06 2002-11-07 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7244396B2 (en) 1999-04-06 2007-07-17 Uab Research Foundation Method for preparation of microarrays for screening of crystal growth conditions
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
US6977723B2 (en) 2000-01-07 2005-12-20 Transform Pharmaceuticals, Inc. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
GB0008563D0 (en) 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
WO2002022154A2 (en) * 2000-09-13 2002-03-21 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
US7601528B1 (en) 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7806980B2 (en) 2000-12-23 2010-10-05 Elan Pharmaceuticals, Inc. Method for crystallizing human beta secretase in complex with an inhibitor
US7670429B2 (en) 2001-04-05 2010-03-02 The California Institute Of Technology High throughput screening of crystallization of materials
US6950757B2 (en) 2001-04-11 2005-09-27 Emerald Biostructures, Inc. Screening methods for identifying ligands
US7524668B1 (en) * 2001-05-10 2009-04-28 Elan Pharmaceuticals, Inc. Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof
US7384773B1 (en) * 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
US7130747B1 (en) * 2001-05-31 2006-10-31 Los Alamos National Security, Llc High throughput screening of ligand binding to macromolecules using high resolution powder diffraction
IL151012A0 (en) * 2001-08-03 2003-02-12 Ribosomes Structure And Protei Ribosomes structure and protein synthesis inhibitors
US20050202505A1 (en) * 2001-08-22 2005-09-15 Philipp Floersheim Method to identify modulators for human 3alpha-hydroxysteroid dehydrogenase
US20030211538A1 (en) * 2001-12-03 2003-11-13 Ming Luo CAP-Gly domain structure and uses thereof
US20040171062A1 (en) * 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
US7469036B2 (en) * 2002-04-19 2008-12-23 Los Alamos National Security, Llc Analysis of macromolecules, ligands and macromolecule-ligand complexes
US7442537B1 (en) 2002-05-10 2008-10-28 Elan Pharmaceuticals, Inc. Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof
US6989392B2 (en) * 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
EA010258B1 (ru) * 2002-07-24 2008-06-30 Кеддем Байо-Сайенс Лтд. Способ поиска лекарственного вещества
WO2006078228A1 (en) * 2002-09-16 2006-07-27 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
WO2004024895A2 (en) * 2002-09-16 2004-03-25 Plexxikon, Inc. Crystal structure of pim-1 kinase
JP2006516095A (ja) * 2002-11-14 2006-06-22 ザ スクリップス リサーチ インスティテュート 脂肪酸アミドヒドロラーゼ（ｆａａｈ）の結晶形
DE60311879T2 (de) 2002-12-23 2007-12-20 Astex Therapeutics Ltd., Cambridge Synthese und screening von liganden mit hilfe von röntgenkristallographie
WO2004078923A2 (en) * 2003-02-28 2004-09-16 Plexxikon, Inc. Pyk2 crystal structure and uses
CA2521766A1 (en) * 2003-04-11 2004-10-28 Sgx Pharmaceuticals, Inc. Compound libraries and methods for drug discovery
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
WO2005017533A1 (de) * 2003-08-06 2005-02-24 Proteros Biostructures Gmbh Verfahren zur identifizierung von schwach bindenden molekülfragmenten mit ligandeneigenschaften, wobei die molekülfragmente als mikrotropfen einer entsprechenden lösung auf den kristall aufgebracht werden
DE10336110B4 (de) * 2003-08-06 2008-01-03 Proteros Biostructures Gmbh Vorrichtung und Verfahren zum Behandeln eines Proteinkristalls
WO2005028624A2 (en) * 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
DE10343522B4 (de) * 2003-09-19 2008-09-18 Proteros Biostructures Gmbh Verfahren und Speichermedium zur Steuerung der Behandlung eines Kristalls mit einer Flüssigkeit
WO2006119542A1 (en) * 2005-05-12 2006-11-16 Cytopia Research Pty Ltd A crystal structure and uses thereof
US20090317850A1 (en) * 2008-06-20 2009-12-24 Tomoko Sunami Crystal Structure of Human 70KD Ribosomal Protein S6 Kinase 1 Kinase Domain
CN101339167B (zh) * 2008-08-27 2011-12-14 中国药科大学 基于靶蛋白亲和选择的活性成分高通量筛选方法
DE102008049675A1 (de) 2008-09-30 2010-04-01 Markus Dr. Heinrich Verfahren zur Herstellung von 3-Aminobiphenylen
US8945303B2 (en) * 2009-03-03 2015-02-03 Institute Of National Colleges Of Technology, Japan Device for crystallizing biopolymer, cell of solution for crystallizing biopolymer, method for controlling alignment of biopolymer, method for crystallizing biopolymer and biopolymer crystal
CN102101886A (zh) 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
JP5598238B2 (ja) * 2010-10-08 2014-10-01 株式会社リコー 画像形成装置
CN106033064B (zh) * 2015-03-10 2019-05-07 上海上药信谊药厂有限公司 胆维丁测定方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112755A (en) 1982-04-15 1992-05-12 Genentech, Inc. Preparation of functional human urokinase proteins

Also Published As

Publication number Publication date
TR200002572T2 (tr) 2000-11-21
EP1068531A2 (en) 2001-01-17
AU2987899A (en) 1999-09-20
SK13242000A3 (sk) 2001-03-12
TR200101200T2 (tr) 2002-02-21
ATE375510T1 (de) 2007-10-15
JP2002506206A (ja) 2002-02-26
CA2321968A1 (en) 1999-09-10
PL343264A1 (en) 2001-07-30
NO20004433D0 (no) 2000-09-05
DE69937292T2 (de) 2008-07-03
WO1999045379A2 (en) 1999-09-10
BR9908563A (pt) 2000-11-21
EP1068531B1 (en) 2007-10-10
AU2887099A (en) 1999-09-20
DE69937292D1 (de) 2007-11-22
WO1999045389A2 (en) 1999-09-10
US6297021B1 (en) 2001-10-02
AU767991B2 (en) 2003-11-27
IL137758A0 (en) 2001-10-31
HUP0101959A3 (en) 2003-10-28
CN100354627C (zh) 2007-12-12
TR200101127T2 (tr) 2002-06-21
TR200101129T2 (tr) 2002-06-21
HUP0101959A2 (hu) 2001-09-28
CN101221138A (zh) 2008-07-16
WO1999045379A3 (en) 1999-11-25
CN1299467A (zh) 2001-06-13
AU2003255167A1 (en) 2003-11-13
BG104802A (bg) 2001-04-30
WO1999045389A3 (en) 2000-02-10
KR20010041653A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
NO20004433D0 (no) Ligandscreening og design ved røntgenkrystallografi
Tan et al. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy
Tung et al. Frequency of mutations in individuals with breast cancer referred for BRCA 1 and BRCA 2 testing using next‐generation sequencing with a 25‐gene panel
Chaurand et al. New methodological approach for the vanadium K-edge X-ray absorption near-edge structure interpretation: Application to the speciation of vanadium in oxide phases from steel slag
Boguta et al. Interactions of Zn (II) ions with humic acids isolated from various type of soils. Effect of pH, Zn concentrations and humic acids chemical properties
Savitz et al. Review of epidemiologic evidence on benzene and lymphatic and hematopoietic cancers
Liu et al. Stress-related gene expression in mice treated with inorganic arsenicals
CA1168967A (en) Diagnostic device for fecal occult blood
Crivianu-Gaita et al. Acoustic wave biosensor for the detection of the breast and prostate cancer metastasis biomarker protein PTHrP
MXPA05004033A (es) Hidroxilasas de asparaginil y moduladores de las mismas.
Holden et al. Sulfur speciation in biochars by very high resolution benchtop Kα X-ray emission spectroscopy
Johnson et al. Adsorption of organic matter at mineral/water interfaces: 5. Effects of adsorbed natural organic matter analogues on mineral dissolution
Solomon et al. Key feature of the catalytic cycle of TNF-α converting enzyme involves communication between distal protein sites and the enzyme catalytic core
de Souza Sierra et al. Application of potentiometry to characterize acid and basic sites in humic substances: testing the BEST7 program with a weak-acid mixture
Cao et al. Ascorbic acid induced the improved oxygen vacancy defects of Bi4O5Br2 and its application on Photoelectrochemical detection of DNA demethylase MBD2 with improved detection sensitivity
Hough et al. Perspective: Structure determination of protein-ligand complexes at room temperature using X-ray diffraction approaches
Winkler et al. Coexisting multi-states in catalytic hydrogen oxidation on rhodium
Blankenburg et al. High-throughput omics technologies: potential tools for the investigation of influences of EMF on biological systems
Lindgren et al. Broad‐Spectrum Antidote Discovery by Untangling the Reactivation Mechanism of Nerve‐Agent‐Inhibited Acetylcholinesterase
JPWO2019049974A1 (ja) 免疫機能評価方法およびその為のｅｌｉｓａシステム
Martra et al. Reactive sites at the surface of crocidolite asbestos
Venkatesan et al. Rapid detection strategies for the ultra-level chemosensing of uranyl ions
Guo et al. Activation of transcription factors NF-kappaB and AP-1 and their relations with apoptosis-associated proteins in hepatocellular carcinoma
Gupta et al. APOBEC3 mutagenesis drives therapy resistance in breast cancer
Reuß et al. Optical In Situ Monitoring of Acid Mine Drainage Remediation: Laboratory and Model Investigation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application